RPP RPN-LFT01-Jacksonville-University Blvd_COMING SOON! 

About this study: 

The purpose of this clinical trial is to find out whether leflutrozole can help improve semen quality in men. Researchers will test three different dose levels of leflutrozole to see how well the medication works.

You may be eligible if you:

• Are a man aged 18 to 49 years.
• Have low testosterone levels confirmed by testing.
• Have low sperm counts on semen testing.
• Have certain hormone levels that meet study requirements.
• Are able to provide semen samples and follow study procedures.

You may not be eligible if you:

• Have significant conditions affecting the testicles, pituitary gland, prostate, heart, liver, or kidneys.
• Have a history of blood clots, osteoporosis, recent cancer, untreated sleep apnea, or substance abuse.
• Have recently used testosterone therapy, anabolic steroids, fertility medications, finasteride, dutasteride, or certain other hormone-related medications.

The study team will review your medical history, medications, and test results to determine if you qualify.\

Why participate?

• Help advance research in heart disease prevention
• Compensation may be available (if applicable)\

Study Details:

Location: Jacksonville, FL

All study- related care is provided at no cost to you or your insurance company.

AZ D9050C00002 PIONEER-PKD ADPKD (FTC) 

About this Study

This study is testing AZD1613, a study medication for people with autosomal dominant polycystic kidney disease (ADPKD).

You may qualify if you:

• Are 18 to 65 years old
• Have a diagnosis of ADPKD
• Have kidney function within the study’s required range
• Weigh at least 45 kg (99 lbs)
• Meet other study-specific health requirements

You may not qualify if you:

• Have certain heart, blood vessel, or kidney conditions that could make participation unsafe
• Have a history of certain serious heart rhythm problems
• Have uncontrolled high blood pressure or significant abnormalities on heart tests (ECGs)
• Have had a recent procedure to treat kidney cysts
• Have certain significant blood, urine, or laboratory test abnormalities

The study team will review your medical history, medications, and test results to determine if you are eligible.

Why participate?

• Help advance research in heart disease prevention
•  Compensation may be available (if applicable)

Study Details: 

Location: Jacksonville, FL 

All study- related care is provided at no cost to you or your insurance company.

VER VER-CLBP-003 Chronic Lower Back Pain

About this study:

This study is testing whether VER-01 can safely reduce pain in adults who have chronic lower back and leg pain caused by irritation or compression of nerves in the lower spine (lumbosacral radiculopathy)

Who Can Join?

• Adults age 18 or older
• Able to sign consent and participate in all study visits and study activities, including using an electronic diary (eDiary)

Who Cannot Join?

• Currently pregnant or breastfeeding
• History of certain serious mental health conditions (such as schizophrenia, bipolar disorder, PTSD, or severe anxiety), or currently taking antipsychotic medication
• Serious heart problems within the past year, including heart attack, heart failure, significant irregular heartbeat, or uncontrolled high blood pressure

Other eligibility requirements may apply.

Why participate?

• Help advance research in heart disease prevention
•  Compensation may be available (if applicable)

About this study: 

This extension study looks at the long-term safety and effectiveness of remibrutinib in people with CSU(Chronic Spontaneous Uticaria“Hives”   who completed a prior study, while also allowing continued access to the medication after the Phase 3 studies, when appropriate.

Who can join:

• You must sign a consent form before any study procedures.

• You must be 18 years or older.
• You must have completed a previous remibrutinib study.
• You should be willing and able to follow the study visits and instructions.

Who cannot join:

• You have a high risk of bleeding or a bleeding disorder.

• You have a history of stomach or intestinal bleeding.
• You need to take blood thinners or medications that affect clotting.
• You have current or past liver disease.
• You have other serious health conditions (such as heart, lung, kidney, immune, or mental health conditions) that could make participation unsafe or affect study results.

Why participate?

• Help advance research in heart disease prevention
• Compensation may be available (if applicable) )

Study Details: 

Location: Jacksonville, FL 

All study-related care is provided at no cost to you or your insurance company.

About this study: 

This study is testing how well new medicines (CagriSema and cagrilintide) help children and teens lose weight.

Who can join?

• Ages 8 to under 18

• Higher body weight for age/height
• Tried diet and exercise for 3+ months without enough success
• Weigh over 45 kg (99 lbs)
• Parent/guardian consent + child agreement
• Normal lab tests

If they have type 2 diabetes:

• Controlled blood sugar

• Only on lifestyle changes or stable metformin

Who cannot join?

• Used weight-loss meds in last 90 days

• Had recent weight-loss surgery/devices

• Uncontrolled thyroidor genetic/hormonal obesity
• Big weight change(>5%) in last 3 months
• Type 1 diabetes

Extra exclusions:

• Without T2D: high blood sugar or diabetes meds

• With T2D: frequent low blood sugar, certain antibodies, other diabetes meds, or serious eye problems

Why participate?

• Help advance research in heart disease prevention
• Compensation may be available (if applicable) )

Study Details: 

Location: Jacksonville, FL 

All study-related care is provided at no cost to you or your insurance company.

NOVO-NN9487-8023 Obesity AMAZE 9

About this Study: 

A research study designed to learn more about how effective zenagamtide tablets may be in helping people who are overweight achieve meaningful weight loss.

Key Inclusion Criteria:

• Age 18-69 years (both inclusive) at the time of signing the informed consent.
• Previous or planned (during the study period) obesity treatment with surgery or a weight loss device. However, the following are allowed if the procedure and removal of the device was uncomplicated:
  1. Liposuction and/or abdominoplasty, if performed > 1 year before screening
  2. Adjustable gastric banding, if the band has been removed > 1 year before screening
  3. Intragastric balloon, if the balloon has been removed > 1 year before screening
  4. Duodenal-jejunal bypass liner (e.g. Endobarrier), if the sleeve has been removed > 1 year before screening
  5. Non-pharmaceutical, non-invasive, biodegradable devices, if last used > 1 year before screening

Key Exclusion Criteria:

• HbA ≥ 6.5% (48 mmol/mol) as measured by the central laboratory at screening
• History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records
• Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment), or amylin analogues within 1 year before screening

Why participate?

• Help advance research in heart disease prevention

• Compensation may be available (if applicable)

Study Details: 

Location: Jacksonville, FL 

All study- related care is provided at no cost to you or your insurance company.

PFI C6491015 VESPER SWITCH Obesity 

About this study

The study aims to learn more about weight management and health outcomes in adults who have been consistently taking wright loss medications.

Who May Be Able to Participate?

You may qualify if:

• You are 18 years of age or older (or the minimum age required by local regulations).
• You have been taking:
  • Semaglutide (Wegovy®) 1.7 mg or 2.4 mg once weekly for at least 6 months, with no dose changes in the last 90 days, or
  • Tirzepatide (Zepbound®) 5 mg, 10 mg, or 15 mg once weekly for at least 6 months, with no dose changes in the last 90 days.
• You have generally taken your medication as prescribed. Up to 3 missed doses in the past 6 months may be allowed if they were missed because of a medical procedure or hospitalization.
• You meet any reproductive health requirements reviewed by the study team.

Who Cannot Participate?

You may not qualify if any of the following apply to you:

Weight-Related Conditions

• Your Body Mass Index (BMI) is less than 25 kg/m² at the screening visit.
• You have had or are planning to have weight-loss surgery.
  • Liposuction or tummy tuck procedures performed more than 1 year ago are allowed.
• You have had, currently have, or plan to have certain weight-loss devices or procedures, such as:
  • Gastric balloon
  • Gastric artery embolization
  • Duodenal-jejunal bypass sleeve
  • Other similar obesity treatments
• Your obesity is caused by certain hormonal or genetic conditions, such as:
  • Cushing’s syndrome
  • MC4R (Melanocortin 4 Receptor) deficiency
  • Prader-Willi syndrome

Diabetes and Hormone-Related Conditions

• You have a history of diabetes.
• Your screening laboratory results suggest that you have diabetes.

Why participate?

• Help advance research in heart disease prevention

• Compensation may be available (if applicable)

Study Details: 

Location: Jacksonville, FL 

All study- related care is provided at no cost to you or your insurance company.

Below is the study criteria information publicly available from Clinicaltrials.gov

• • • 18 Years to 70 Years (Adult, Older Adult)
    • Diagnosis of HeFH or premature CAD

• • • Homozygous familial hypercholesterolemia
    • Active or history of chronic liver disease
    • Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe
    • Clinically significant or abnormal laboratory values as defined by the protocol

Click here to view this research study on clinicaltrials.gov

Gene Editing Research for High Cholesterol  

Advancing Cholesterol Care Through Gene Editing Research 

Do you have high cholesterol that has been difficult to control despite treatment? You may qualify for a research study exploring a new approach to managing cholesterol through gene editing. 

At Jacksonville Center for Clinical Research, we are committed to advancing heart health through cutting-edge clinical research—and you could play an important role. 

About the Study 

This research study is a Phase 1, first-in-human clinical trial evaluating an investigational gene-editing therapy for individuals with dyslipidemia that has not responded to available treatments. 

The study is open-label and multicenter, meaning participants will receive the study treatment, and the trial is being conducted at multiple research locations. This is a single-arm study, so all participants will receive the investigational therapy. 

Who May Qualify? 

You may be eligible to participate if you: 

✅ Are 18 to 75 years of age  

✅ Have been diagnosed with persistent dyslipidemias  

✅ Have been on standard cholesterol medications for at least 12 weeks, but levels are still not well controlled. 

Participants will receive study-related care at no cost, and no insurance is required. Compensation is available for qualified participants.